2014
DOI: 10.1016/j.jinf.2013.11.010
|View full text |Cite
|
Sign up to set email alerts
|

Restoration of lung surfactant protein D by IL-6 protects against secondary pneumonia following hemorrhagic shock

Abstract: Summary Objectives To identify novel approaches to improve innate immunity in the lung following trauma complicated by hemorrhagic shock (T/HS) for prevention of nosocomial pneumonia. Methods We developed a rat model of T/HS followed by Pseudomonas aeruginosa (PA) pneumonia to assess the effect of alveolar epithelial cell (AEC) apoptosis, and its prevention by IL-6, on lung surfactant protein (SP)-D protein levels, lung bacterial burden, and survival from PA pneumonia, as well as to determine whether AEC ap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 46 publications
0
7
0
Order By: Relevance
“…In addition, administration of a NO scavenger also resulted in reduced lung injury and reduced activation of NF-kB and STAT3 after resuscitated hemorrhagic shock (Hierholzer et al, 2002), presumably through downregulation of acute inflammation (Hierholzer et al, 2002). Importantly, resuscitation from hemorrhagic shock also resulted in apoptosis of lung type I alveolar endothelial cells (Moran et al, 2009), liver hepatocytes (Moran et al, 2008), and cardiomyocytes (Thacker et al, 2013), which resulted in increased susceptibility to pneumonia (Thacker et al, 2014) and sepsis following intraperitoneal bacterial challenge (Arikan et al, 2006). Importantly, apoptosis of these critical parenchymal cells in the lung, liver, and heart and the increased susceptibility to pneumonia and bacterial peritonitis could be reversed by administration of IL-6 at the start of resuscitation; this action of IL-6 was mediated by activation of STAT3.…”
Section: F Ischemia and Reperfusion Stressmentioning
confidence: 99%
“…In addition, administration of a NO scavenger also resulted in reduced lung injury and reduced activation of NF-kB and STAT3 after resuscitated hemorrhagic shock (Hierholzer et al, 2002), presumably through downregulation of acute inflammation (Hierholzer et al, 2002). Importantly, resuscitation from hemorrhagic shock also resulted in apoptosis of lung type I alveolar endothelial cells (Moran et al, 2009), liver hepatocytes (Moran et al, 2008), and cardiomyocytes (Thacker et al, 2013), which resulted in increased susceptibility to pneumonia (Thacker et al, 2014) and sepsis following intraperitoneal bacterial challenge (Arikan et al, 2006). Importantly, apoptosis of these critical parenchymal cells in the lung, liver, and heart and the increased susceptibility to pneumonia and bacterial peritonitis could be reversed by administration of IL-6 at the start of resuscitation; this action of IL-6 was mediated by activation of STAT3.…”
Section: F Ischemia and Reperfusion Stressmentioning
confidence: 99%
“…Previous studies have suggested that IL-6 is a multifunctional cytokine with time-, dose-and organ-specific functions[32]. For example, IL-6 is known to decrease T cell apoptosis and promote epithelial survival in the GI system[33], and to ameliorate lung injury by re-establishing surfactant levels[34]. Similarly, MCP-1 is known to play a protective role in bleomycin-induced lung injury[35].…”
Section: Discussionmentioning
confidence: 99%
“…Additional potential treatments that have been suggested include the use of covalently bound complexes, comprising antibody crosslinked to point mutated SP-D ( 299 , 488 ), or introduction of specific N-linked glycans ( 489 ), in enhanced anti-viral or anti-bacterial therapies ( 490 ); for example, genetically engineered SP-D, which is resistant to proteolysis and relevant for the treatment of P. aeruginosa ( 250 , 260 ); reduction of lung inflammation and injury after allogeneic hematopoietic stem cell transplantation ( 491 ); inclusion of SP-D in nasal spray for chronic rhinosinusitis with polyps ( 13 ); alleviation of pneumonia severity and intestinal injury in Staphylococcus aureus pneumonia ( 441 ) or pulmonary aspergillosis ( 205 ). Moreover, therapeutic approaches have been suggested to increase transcription of SP-D ( 62 , 492 ).…”
Section: Perspectives: Recombinant Sp-d Treatmentmentioning
confidence: 99%